Related Experiment Video
Updated: Apr 26, 2026
09:37
Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information
Published on: August 15, 2019
8.9K
Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties
Katherine A Johansen Taber1, Barry D Dickinson1
1Department of Science and Biotechnology, American Medical Association, Chicago, IL, USA.
Pharmacogenomics and Personalized Medicine
|July 22, 2014
Summary
Physicians lack knowledge and confidence in using pharmacogenomic testing for drug therapy. Accessible, clinically-focused educational resources are needed to bridge this pharmacogenomic knowledge gap.
Area of Science:
- Clinical Pharmacology
- Genetics
- Medical Education
Background:
- Pharmacogenomic testing can enhance drug therapy safety and efficacy.
- Physicians report a deficit in pharmacogenomic knowledge and preparedness for clinical implementation.
- This study investigates physician knowledge gaps and educational needs in pharmacogenomics.
Purpose of the Study:
- To assess the current level of pharmacogenomic knowledge among physicians.
- To identify physicians' needs for educational resources regarding pharmacogenomic testing.
- To inform the development of effective pharmacogenomic education.
Main Methods:
- Surveys were administered to primary care physicians, cardiologists, and psychiatrists.
- The surveys assessed physician familiarity, confidence, and training in pharmacogenomics.
- Physicians' preferences for educational resource content and format were collected.
Main Results:
- Most physicians reported limited familiarity with pharmacogenomics but varying confidence in genetics' influence on drug response.
- Formal pharmacogenomic training was uncommon, with many unsure about appropriate test selection.
- Physicians desire electronic resources with interpretation guidance, prescribing recommendations, and lab information.
Conclusions:
- Significant pharmacogenomic knowledge gaps persist among physicians.
- Physicians require clinically relevant and accessible educational tools for effective implementation.
- Targeted educational interventions are crucial for appropriate clinical use of pharmacogenomics.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
246
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
246
01:27Pharmacogenetics of Drug Metabolism: Overview
191
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
191
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
156
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
156
01:29Pharmacogenomics: Identification of New Drug Targets
119
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119
01:27Principles of Pharmacogenetics: Types of Genetic Variants
135
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
135
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
330
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
330